Definiteness, Animacy, and NP Ordering

Proceedings of the 3rd Annual Meeting of the Berkeley Linguistics Society (1977), pp. 418-42

Neutrophil/Lymphocytes Ratio and Haemoglobin Electrophoretic Pattern in an Undergraduate Student’s Population Rivers State University, Port Harcourt, Nigeria

Neutrophil/lymphocyte ratio (NLR) is a very cheap and accurate method of accessing inflammation and is fast emerging as a prognostic biomarker in many diseases. This study determines the Neutrophil/lymphocyte ratio and haemoglobin electrophoretic patterns in an undergraduate student’s population at Rivers State University, Port Harcourt, Nigeria. One hundred and fifty (150) undergraduate students aged between 17 and 30 years old were recruited for the study. Five millimeters (5ml) of venous blood was collected from each participants into ethylene diamine tetraacetic acid (EDTA) vacutainer bottle for the determination of haemoglobin genotype using cellulose acetate electrophoresis method while the neutrophil/lymphocyte ratio was calculated from neutrophil and lymphocyte values obtained from BC 5000 Mindray Hematology Auto-Analyzer. The results obtained showed that the mean±SD value of Neutrophil/Lymphocyte ratio was 1.21 ± 0.07 for male and 1.14 ± 0.06 for female participants with both within normal reference ranges and with no significant difference (p=0.4692). 100 (66.7%) subjects had haemoglobin genotype AA (HbAA) out of which 48 (32%) male, 52 (34.7%) female while 50 (33.3%) participants had haemoglobin genotype AS (HbAS) of which 24 (16%) male, 26 (17.3%) female. No haemoglobin genotype SS/SC (HbSS/HbSC) traits were seen in the study population. Furthermore, results also showed that haemoglobin genotype and sex had no effects on the neutrophil/lymphocyte ratio (p=0.05). This study shows a 66.7%, 33.3%, and 0% expression for HbAA, HbAS, and HbSS/HbSC, respectively, and that the Neutrophil/Lymphocyte ratio is within the normal reference range. Further studies to include other haemoglobin variants such as haemoglobin SS (HbSS) and haemoglobin SC (HbSC) is recommended

The Grammaticalization of Complementizers

Proceedings of the Fourteenth Annual Meeting of the Berkeley Linguistics Society (1988), pp. 364-37

Definiteness, Animacy, and NP Ordering

Proceedings of the 3rd Annual Meeting of the Berkeley Linguistics Society (1977), pp. 418-42

Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.

International audienceBACKGROUND: There is a need for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect profile. METHODS: We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments containing 15% paromomycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishmania major in Tunisia. We randomly assigned 375 patients with one to five ulcerative lesions from cutaneous leishmaniasis to receive a cream containing 15% paromomycin-0.5% gentamicin (called WR 279,396), 15% paromomycin alone, or vehicle control (with the same base as the other two creams but containing neither paromomycin nor gentamicin). Each lesion was treated once daily for 20 days. The primary end point was the cure of the index lesion. Cure was defined as at least 50% reduction in the size of the index lesion by 42 days, complete reepithelialization by 98 days, and absence of relapse by the end of the trial (168 days). Any withdrawal from the trial was considered a treatment failure. RESULTS: The rate of cure of the index lesion was 81% (95% confidence interval [CI], 73 to 87) for paromomycin-gentamicin, 82% (95% CI, 74 to 87) for paromomycin alone, and 58% (95% CI, 50 to 67) for vehicle control (P<0.001 for each treatment group vs. the vehicle-control group). Cure of the index lesion was accompanied by cure of all other lesions except in five patients, one in each of the paromomycin groups and three in the vehicle-control group. Mild-to-moderate application-site reactions were more frequent in the paromomycin groups than in the vehicle-control group. CONCLUSIONS: This trial provides evidence of the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerative L. major disease. (Funded by the Department of the Army; ClinicalTrials.gov number, NCT00606580.)